references
DEVELOPMENT
Testing the balance between the safety and efficacy of a drug has to be conducted in large-scale, Phase III trials. This trial phase is necessary to obtain authorization from regulatory authorities and register the drug, in order for countries to produce, import, or distribute the drugs.
Fexinidazole
HAT
Health Institute, Switzerland; Institute of Tropical Medicine Antwerp, Belgium; Médecins Sans Frontières; Institut de Recherche pour le Développement, France; Institut National de Recherche Biomédicale, DRC; HAT Platform; National Control Programmes of the Democratic Republic of Congo and the Central African Republic
Objective: Develop and register fexinidazole as a new drug for the treatment of stage 2 HAT caused by T. b. gambiense, ideally also for stage 1 HAT and for children between 6 and 14 years old. Main partners: Sanofi, France; Swiss Tropical and Public
Belgium; Médecins Sans Frontières, the Netherlands; Uppsala University, Sweden; Gilead Sciences, USA; LEAP; The Netherlands Cancer Institute, the Netherlands; Utrecht University, the Netherlands; BaseCon, Denmark; UBC, Switzerland
MF/Paromomycin combination therapy
for Africa
LEISHMANIASIS
New treatments for PKDL
for Asia/Africa
LEISHMANIASIS
Objective: Determine the safety and efficacy of two treatment regimens for patients with PKDL, mainly in the Indian Sub-continent and East Africa. Main partners: International Centre for Diarrhoeal Disease
Objective: Assess the safety and efficacy of two combination regimens of paromomycin and miltefosine for the treatment of primary VL patients in East Africa. Main partners: Kenya Medical Research Institute, Kenya;
Makerere University, Uganda; Utrecht University, the Netherlands
New treatments for HIV/VL co-infection
for Africa
LEISHMANIASIS
Research, Bangladesh; Rajendra Memorial Research Institute of Medical Sciences, India; Kala Azar Medical Research Centre, India; Institute of Medical Sciences, Banaras Hindu University, India; Uppsala University, Sweden; Institute of Endemic Disease, Khartoum University, Sudan; Ministry of Health, Sudan; LEAP
New VL treatments
for Latin America
LEISHMANIASIS
Ababa University, Ethiopia; London School of Hygiene and Tropical Medicine, UK; Institute of Tropical Medicine Antwerp,
Objective: Identify and deliver a safe and highly effective treatment for VL in HIV co-infected patients that will improve long-term survival of these patients. Main partners: Gondar University Hospital, Ethiopia; Addis
Objective: Assess the efficacy and safety of amphotericin B deoxycholate, AmBisome®, and AmBisome® combined with Glucantime®, as compared to the first-line treatment, Glucantime®, for the treatment of VL patients in Brazil, supporting the Brazilian Ministry of Health and its partners. Main partners: BRAZIL: Rene Rachou Research Center–
Fiocruz-MG, Belo Horizonte; Paediatric Hospital Joao Paulo II – FHEMIG, Belo Horizonte; Brasilia University; Montes Claros
12
• R&D Portfolio
